Vaxrevia Data Release
Hold onto your shirt. MHRA have answered the VaxRevia questions:
The Oxford/AstraZeneca (Vaxrevia) vaccine, indicated in adults, was linked to a rare but serious side effect called thrombosis with thrombocytopenia syndrome (TTS). On 27 March 2024, the European Commission withdrew the marketing authorisation for Vaxzevria.
In March 2021, David Spiegelhalter, writing in the Guardian, said, “There’s no proof that the Oxford vaccine causes blood clots.”
On the 11th of March, the European Medicines Agency said the Oxford/AstraZeneca Covid vaccine can continue to be used during an investigation into thromboembolic events. They had received notification of 30 cases of “thromboembolic events” among 5 million people who had received the vaccine in Europe.
By 7 April, the UK JCVI advised that the vaccine should be restricted to people aged 30 and over due to the risk of blood clots.
Given the delays and the issues with access to data, we FOIed the MHRA to request the number of notifications for cardiovascular (and separately for thromboembolic) events in relatio…
